Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia
Publication
, Conference
Petersdorf, S; Kopecky, K; Stuart, RK; Larson, RA; Nevill, TJ; Stenke, L; Slovak, ML; Tallman, MS; Willman, CL; Erba, H; Appelbaum, FR
Published in: BLOOD
November 20, 2009
Duke Scholars
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 20, 2009
Volume
114
Issue
22
Start / End Page
326 / 327
Location
New Orleans, LA
Publisher
AMER SOC HEMATOLOGY
Conference Name
51st Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Petersdorf, S., Kopecky, K., Stuart, R. K., Larson, R. A., Nevill, T. J., Stenke, L., … Appelbaum, F. R. (2009). Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia. In BLOOD (Vol. 114, pp. 326–327). New Orleans, LA: AMER SOC HEMATOLOGY.
Petersdorf, Stephen, Kenneth Kopecky, Robert K. Stuart, Richard A. Larson, Thomas J. Nevill, Leif Stenke, Marilyn L. Slovak, et al. “Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.” In BLOOD, 114:326–27. AMER SOC HEMATOLOGY, 2009.
Petersdorf S, Kopecky K, Stuart RK, Larson RA, Nevill TJ, Stenke L, et al. Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia. In: BLOOD. AMER SOC HEMATOLOGY; 2009. p. 326–7.
Petersdorf, Stephen, et al. “Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.” BLOOD, vol. 114, no. 22, AMER SOC HEMATOLOGY, 2009, pp. 326–27.
Petersdorf S, Kopecky K, Stuart RK, Larson RA, Nevill TJ, Stenke L, Slovak ML, Tallman MS, Willman CL, Erba H, Appelbaum FR. Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia. BLOOD. AMER SOC HEMATOLOGY; 2009. p. 326–327.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 20, 2009
Volume
114
Issue
22
Start / End Page
326 / 327
Location
New Orleans, LA
Publisher
AMER SOC HEMATOLOGY
Conference Name
51st Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology